Fulgent Reports Third Quarter 2024 Financial Results

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT) reported Q3 2024 financial results with total revenue of $71.7 million, representing a 9% year-over-year growth in core revenue. The company posted a GAAP loss of $14.6 million (-$0.48 per share) and non-GAAP income of $9.4 million ($0.31 per share). The company maintains strong liquidity with $815.4 million in cash and investments.

Fulgent reiterates its full-year 2024 core revenue guidance of $280 million and improves its GAAP loss guidance from -$1.95 to -$1.70 per share. The company also revised its non-GAAP outlook from a loss of $0.30 per share to an income of $0.33 per share.

Positive

• 9% year-over-year growth in core revenue to $71.7 million
• Strong liquidity position with $815.4 million in cash and investments
• Improved earnings guidance for 2024
• Sequential growth in all three areas of Laboratory Services

Negative

• GAAP loss of $14.6 million in Q3 2024
• Projected full-year GAAP loss, despite improvement in guidance

Insights

Financial Analyst

The Q3 2024 results show mixed performance with notable metrics. Core revenue grew 9% year-over-year to $71.7 million, demonstrating organic growth in the laboratory services segment. However, the company posted a GAAP loss of $14.6 million ($0.48 per share), while maintaining a strong cash position of $815.4 million.

The improved full-year 2024 guidance is particularly noteworthy, with management raising EPS expectations from a loss of $1.95 to $1.70 per share and non-GAAP metrics shifting from a $0.30 loss to $0.33 income per share. The company's substantial cash reserves provide significant operational flexibility and potential for strategic investments.

Medical Research Analyst

The company's therapeutic development pipeline shows promising advancement, particularly with FID-007's Phase 2 clinical trial in Head and Neck Cancer reporting encouraging preliminary results. The progression of FID-022 through preclinical studies toward IND application indicates momentum in the drug development segment. The sequential growth across all three areas of Laboratory Services suggests successful diversification beyond their historical COVID-19 testing focus.

• Total Revenue of $71.7 million
• Core Revenue grows 9% year-over-year to $71.7 million
• Reiterates Full Year 2024 Core Revenue Guidance of $280 million, Improves Earnings Per Share Guidance for 2024

EL MONTE, Calif.--(BUSINESS WIRE)-- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2024.

Third Quarter 2024 Results:

• Total Revenue of $71.7 million
• Core Revenue¹ grew 9% year-over-year to $71.7 million
• GAAP loss of $14.6 million, or ($0.48) per share
• Non-GAAP income of $9.4 million, or $0.31 per share
• Adjusted EBITDA income of $0.4 million
• Cash, cash equivalents, restricted cash, and investments in marketable securities of $815.4 million as of September 30, 2024

Note:
	1) Core Revenue is revenue calculated in accordance with GAAP minus revenue from COVID-19 testing products and services including COVID-19 NGS testing revenue, each as calculated in accordance with GAAP.

Non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin, are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), GAAP gross profit and margin, and GAAP operating income (loss) and margin, in the accompanying tables.

Ming Hsieh, Chairperson of the Board of Directors and Chief Executive Officer, said, “We continue to see good momentum in our business, with Laboratory Services fueling our initiatives and exhibiting sequential growth in all three areas of our Laboratory Services business for the quarter. In Therapeutics Development, we are encouraged by the preliminary results we are seeing from initial patients being treated in our Phase 2 clinical trial of FID-007 in Head and Neck Cancer, and we continue to move our next candidate, FID-022, through preclinical studies toward an Investigational New Drug (IND) application.”

Paul Kim, Chief Financial Officer, said, “We are pleased with our financial performance in the third quarter and our trajectory for the remainder of 2024, as we continue to grow core revenue and improve operations.”

Outlook:

For the full year 2024, Fulgent expects:

• Core Revenue of approximately $280 million
• GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
• Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
• Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*

*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company’s ongoing stock repurchase program or other expenditures outside the ordinary course of business.

Conference Call Information

Fulgent will host a conference call for the investment community today at 8:30 AM ET (5:30 AM PT) to discuss its third quarter 2024 results. The call may be accessed through a live audio webcast in the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

Note Regarding Non-GAAP Financial Measures

Certain information set forth in this press release and/or to be discussed on the Company’s earnings call, including non-GAAP income (loss), non-GAAP income (loss) per share, adjusted EBITDA income (loss), non-GAAP gross profit and margin, and non-GAAP operating income (loss) and margin are non-GAAP financial measures. Fulgent believes this information is useful to investors because it provides a basis for measuring the performance of the Company’s business, excluding certain income or expense items that management believes are not directly attributable to the Company’s operating results. Fulgent defines non-GAAP income (loss) as net income (loss) calculated in accordance with accounting principles generally accepted in the United States of America, or GAAP, plus amortization of intangible assets, plus equity-based compensation expenses, plus impairment of available-for-sale debt securities, plus or minus the non-GAAP tax effect, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. The non-GAAP tax effect was calculated by excluding from the GAAP provision the impact of the amortization of intangible assets, equity-based compensation expenses, and impairment of available-for-sale debt securities. Fulgent defines adjusted EBITDA income (loss) as GAAP income (loss) plus or minus interest (expense) income, plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus depreciation and amortization, plus impairment of available-for-sale debt securities, and plus or minus other charges or gains, as identified, that management believes are not representative of the Company’s operations. Fulgent defines non-GAAP gross profit as gross profit calculated in accordance with GAAP plus equity-based compensation included in cost of revenue as shown in the table below. Fulgent defines non-GAAP gross margin by taking non-GAAP gross profit and dividing it by GAAP revenue. Fulgent defines non-GAAP operating profit (loss) by taking GAAP operating profit (loss) and adding equity-based compensation and amortization of intangible assets. Non-GAAP operating margin is calculated by taking non-GAAP operating profit (loss) and dividing by GAAP revenue. Fulgent may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA income (loss); accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of net income (loss), gross profit and margin, and operating income (loss) and margin, in evaluating the Company’s operating performance. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent may not be comparable to similarly titled metrics reported by other companies.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; guidance, including guidance regarding expected quarterly and annual financial results, core revenues, GAAP loss, non-GAAP loss, and cash, cash equivalents and investments in marketable securities; evaluations and judgments regarding the stability of certain revenue sources, the Company’s cash position and sufficiency of its resources, momentum, trajectory, vision, future opportunities and future growth of the Company’s testing and laboratory services, technologies and expansion; the Company’s research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials, including any implication that interim or preliminary data will be representative of final data; the Company’s identification and evaluation of opportunities and its ability to capitalize on opportunities, capture market share, or expand its presence in certain markets; and the Company’s ability to continue to grow its business.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the Company’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on the Company’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the market potential for, and the rate and degree of market adoption of, the Company’s tests; its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the Company’s ability to maintain the low internal costs of its business model; the Company’s ability to maintain an acceptable margin; risks related to volatility in the Company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the Company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the Company’s revenue; the Company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests and testing services; the Company’s level of success in establishing and obtaining the intended benefits from partnerships, strategic investments, joint ventures, acquisitions, or other relationships; the success of the Company’s development efforts, including the Company’s ability to progress its candidates through clinical trials on the timelines expected; the Company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and the Company’s ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the Company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The Company’s reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 28, 2024, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on the Company’s website upon their filing with the SEC. These reports contain more information about the Company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release.

FULGENT GENETICS, INC.
Condensed Consolidated Balance Sheet Data
September 30, 2024 and December 31, 2023
(in thousands)
		September 30, 2024					December 31, 2023
ASSETS:
Cash and cash equivalents		$	58,042				$	97,473
Investments in marketable securities			757,259					750,252
Accounts receivable, net			57,315					51,132
Property, plant, and equipment, net			106,810					83,464
Other assets			254,337					253,007
Total assets		$	1,233,763				$	1,235,328
LIABILITIES & EQUITY:
Accounts payable, accrued liabilities and other liabilities		$	98,865				$	102,042
Total stockholders’ equity			1,134,898					1,133,286
Total liabilities & equity		$	1,233,763				$	1,235,328

FULGENT GENETICS, INC.
Condensed Consolidated Statement of Operations Data
Three and Nine Months Ended September 30, 2024 and 2023
(in thousands, except per share data)
(unaudited)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenue		$	71,743			$	84,687			$	207,256			$	218,708
Cost of revenue (1)			44,972				44,843				131,890				139,481
Gross profit			26,771				39,844				75,366				79,227
Operating expenses:
Research and development (1)			11,783				10,014				36,703				29,488
Selling and marketing (1)			9,124				10,161				26,708				30,967
General and administrative (1)			20,950				17,498				63,765				57,293
Amortization of intangible assets			1,993				1,957				5,973				5,887
Total operating expenses			43,850				39,630				133,149				123,635
Operating (loss) income			(17,079	)			214				(57,783	)			(44,408	)
Interest income			8,090				6,472				23,181				15,802
Interest expense			(14	)			(70	)			210				(625	)
Impairment of available-for-sale debt securities			(10,073	)			—				(10,073	)			—
Other income, net			544				244				554				342
Total other (expense) income, net			(1,453	)			6,646				13,872				15,519
(Loss) income before income taxes			(18,532	)			6,860				(43,911	)			(28,889	)
(Benefit from) provision for income taxes			(3,838	)			20,326				(6,281	)			12,016
Net loss from consolidated operations			(14,694	)			(13,466	)			(37,630	)			(40,905	)
Net loss attributable to noncontrolling interests			46				359				810				1,229
Net loss attributable to Fulgent		$	(14,648	)		$	(13,107	)		$	(36,820	)		$	(39,676	)
Net loss per common share attributable to Fulgent:
Basic		$	(0.48	)		$	(0.44	)		$	(1.22	)		$	(1.33	)
Diluted		$	(0.48	)		$	(0.44	)		$	(1.22	)		$	(1.33	)
Weighted-average common shares:
Basic			30,416				30,013				30,095				29,789
Diluted			30,416				30,013				30,095				29,789
(1) Equity-based compensation expense was allocated as follows:
Cost of revenue		$	1,940			$	2,621			$	5,948			$	7,374
Research and development			3,583				3,782				11,563				10,900
Selling and marketing			931				1,189				2,983				3,644
General and administrative			4,466				3,310				13,579				9,572
Total equity-based compensation expense		$	10,920			$	10,902			$	34,073			$	31,490

FULGENT GENETICS, INC.
Non-GAAP Income (Loss) Reconciliation
Three and Nine Months Ended September 30, 2024 and 2023
(in thousands, except per share data)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Net loss attributable to Fulgent		$	(14,648	)		$	(13,107	)		$	(36,820	)		$	(39,676	)
Amortization of intangible assets			1,993				1,957				5,973				5,887
Equity-based compensation expense			10,920				10,902				34,073				31,490
Impairment of available-for-sale debt securities			10,073				—				10,073				—
Non-GAAP tax effect (1)			1,100				(11,402	)			569				(18,267	)
Non-GAAP income (loss) attributable to Fulgent		$	9,438			$	(11,650	)		$	13,868			$	(20,566	)
Net loss per common share attributable to Fulgent:
Basic		$	(0.48	)		$	(0.44	)		$	(1.22	)		$	(1.33	)
Diluted		$	(0.48	)		$	(0.44	)		$	(1.22	)		$	(1.33	)
Non-GAAP income (loss) per common share attributable to Fulgent:
Basic		$	0.31			$	(0.39	)		$	0.46			$	(0.69	)
Diluted		$	0.31			$	(0.39	)		$	0.46			$	(0.69	)
Weighted average common shares:
Basic			30,416				30,013				30,095				29,789
Diluted			30,679				30,013				30,404				29,789

(1) Tax rates as follows:
During the three and nine months ended September 30, 2024 and 2023, the Company calculated an income tax provision on a non-GAAP basis.

FULGENT GENETICS, INC.
Non-GAAP Adjusted EBITDA Reconciliation
Three and Nine Months Ended September 30, 2024 and 2023
(in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Net loss attributable to Fulgent		$	(14,648	)		$	(13,107	)		$	(36,820	)		$	(39,676	)
Interest income, net			(8,076	)			(6,402	)			(23,391	)			(15,177	)
(Benefit from) provision for income taxes			(3,838	)			20,326				(6,281	)			12,016
Equity-based compensation expense			10,920				10,902				34,073				31,490
Depreciation and amortization			5,920				6,419				18,736				19,610
Impairment of available-for-sale debt securities			10,073				—				10,073				—
Adjusted EBITDA		$	351			$	18,138			$	(3,610	)		$	8,263

FULGENT GENETICS, INC.
Non-GAAP Operating Margin
Three and Nine Months Ended September 30, 2024 and 2023
(in thousands)
		Three Months Ended September 30,								Nine Months Ended September 30,
		2024				2023				2024				2023
Revenue		$	71,743			$	84,687			$	207,256			$	218,708
Cost of revenue			44,972				44,843				131,890				139,481
Gross profit			26,771				39,844				75,366				79,227
Gross margin			37.3	%			47.0	%			36.4	%			36.2	%
Equity-based compensation included in cost of revenue			1,940				2,621				5,948				7,374
Non-GAAP gross profit			28,711				42,465				81,314				86,601
Non-GAAP gross margin			40.0	%			50.1	%			39.2	%			39.6	%
Operating expenses			43,850				39,630				133,149				123,635
Equity-based compensation included in operating expenses			8,980				8,281				28,125				24,116
Amortization of intangible assets			1,993				1,957				5,973				5,887
Non-GAAP operating expenses			32,877				29,392				99,051				93,632
Non-GAAP operating loss		$	(4,166	)		$	13,073			$	(17,737	)		$	(7,031	)
Non-GAAP operating margin			-5.8	%			15.4	%			-8.6	%			-3.2	%

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241107037183/en/

Investor Relations Contact:

The Blueshirt Group

Melanie Solomon, melanie@blueshirtgroup.com

Source: Fulgent Genetics, Inc.

FAQ

What was Fulgent's (FLGT) revenue in Q3 2024?

Fulgent reported total revenue of $71.7 million in Q3 2024, representing a 9% year-over-year growth in core revenue.

What is Fulgent's (FLGT) full-year 2024 revenue guidance?

Fulgent maintains its full-year 2024 core revenue guidance of approximately $280 million.

What was Fulgent's (FLGT) Q3 2024 earnings per share?

Fulgent reported a GAAP loss of $0.48 per share and non-GAAP income of $0.31 per share in Q3 2024.

How much cash and investments does Fulgent (FLGT) have?

As of September 30, 2024, Fulgent had $815.4 million in cash, cash equivalents, restricted cash, and investments in marketable securities.